SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Mary McLeod Bethune

PatientMary McLeod Bethune
Date of birth1953-07-10
IdentifiersMRN HR-ML043-SYN; SSN (made up) 000-43-2195
Document date2026-03-23
AuthorViola Harrington-Mbeki, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Diagnosis visit: lung function, FeNO and echocardiogram results with the pulmonology consultation. [S]

History of Present Illness

Mrs. Bethune returns two weeks after her first visit. This morning she had spirometry before and after albuterol, a diffusion test and FeNO in the pulmonary function laboratory, and an echocardiogram, and she then saw Dr. Oyelowo-Brandt. Her symptoms are unchanged: she wakes with cough and a tight chest two or three nights a week and is breathless on one flight of stairs; she has used albuterol most days. Her home blood pressure readings over the week averaged 144/84. She has heartburn two or three evenings a week and a blocked nose most days. She asks plainly whether this is asthma, her heart or her weight. She has had no thoughts of self-harm. [S]

ElementDetail
Tests this morningSpirometry with bronchodilator response, DLCO, FeNO and transthoracic echocardiogram
Home blood pressureAverage 144/84 over seven days
Her questionIs it asthma, her heart, or her weight?

Review of Systems

SystemResultFinding
RespiratoryPositiveNight cough and chest tightness two or three nights a week; breathless on one flight; wheeze with colds and dust
CardiovascularNegativeNo chest pain, orthopnea needing extra pillows, ankle swelling or palpitations
Ears, nose, mouth, and throatPositiveBlocked nose, postnasal drip and reduced smell
GastrointestinalPositiveHeartburn two or three evenings a week; no trouble swallowing
ConstitutionalNegativeNo fever or weight loss; weight 87.6 kg
PsychiatricNegativeDetermined; no low mood

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid)Two puffs every 4 hours as needed; she uses it most daysRespiratory tract route2025-11-03 to 2026-03-23completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayOne inhalation twice daily plus one as neededRespiratory tract route2026-03-23 to 2026-06-15completedS
Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septumTwo sprays each nostril dailyNasal route2026-03-23activeS
Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid sprayTwo sprays each nostril up to four times dailyNasal route2026-03-23activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeksOne capsule daily before breakfastOral route2026-03-23 to 2026-05-18completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-23Body height163cmS
2026-03-23Body weight87.6kgS
2026-03-23Body mass index (BMI) [Ratio]33kg/m2S
2026-03-23Systolic blood pressure146mm[Hg]S
2026-03-23Diastolic blood pressure86mm[Hg]S
2026-03-23Heart rate78/minS
2026-03-23Respiratory rate18/minS
2026-03-23Body temperature36.6CelS
2026-03-23Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-23FEV1 --pre bronchodilation1.3LLower limit of normal, GLI Global race-neutral equations; predicted 2.03 LLowS
2026-03-23FEV1 --post bronchodilation1.57LLower limit of normal, GLI Global race-neutral equations; predicted 2.03 LNormalS
2026-03-23FEV1 measured/predicted64%GLI Global race-neutral equationsLowS
2026-03-23FEV1/FVC0.64{ratio}>=0.7LowS
2026-03-23FEV1/FVC --post bronchodilation0.72{ratio}0.70 or more after bronchodilator: no persistent airflow obstructionNormalS
2026-03-23Diffusion capacity.carbon monoxide17.2mL/min/mm[Hg]Lower limit of normal, GLI race-neutral; predicted 18.6NormalS
2026-03-23Fractional concentration of exhaled nitric oxide46[ppb]Above 50 ppb high; 25 to 50 intermediate (ATS)HighS
2026-03-23Left ventricular Ejection fraction62%53-73%NormalS
2026-03-23IgE [Units/volume] in Serum or Plasma210[IU]/mL<=100 [IU]/mLHighS
2026-03-23Total score [ACT]14{score}S

Physical Exam

Vital signs recorded on 2026-03-23; see the Vital Signs section. [S]

SystemFinding
GeneralDignified and composed; speaks in full sentences; weight 87.6 kg; blood pressure 146/86, pulse 78; oxygen saturation 96 percent
EyesFundoscopy: mild arteriolar narrowing; no hemorrhages or exudates
NoseSwollen, pale inferior turbinates; no polyps visible by anterior rhinoscopy
RespiratoryScattered expiratory wheeze on forced expiration; no crackles
CardiovascularRegular rhythm; no murmur or gallop; jugular venous pressure not raised; no edema; foot pulses present

Problems

ProblemClinical statusVerificationCodeProvenance
Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram bookedresolvedconfirmed R06.2S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit.
Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialistactiveconfirmed R09.81S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy.
Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight lossactiveconfirmed K21.9S — Synthetic comorbidity of asthma; not a claim about her real health.
Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about itactiveconfirmed E66.811S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight.
Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol aloneactiveconfirmed J45.40S — Synthetic modern confirmation linked to her documented chronic asthma.
Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mLactiveconfirmed I11.9S — Synthetic finding of the modern work-up; not a claim about her real heart.
Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertensionactiveconfirmed E78.5S — Synthetic cardiovascular risk factor.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingSpirometry with bronchodilator response, read with race-neutral equations; DLCOAt diagnosis, before starting controller therapyCompleted todayFEV1 1.30 L (64 percent) to 1.57 L (+270 mL, +21 percent); FEV1/FVC 0.64 to 0.72; DLCO 17.2 (92 percent)
ImagingFeNOWhen the diagnosis is uncertain, and to monitor response (NAEPP, conditional)Completed today46 ppb, raised
LaboratoryBlood eosinophils and total and specific IgE (phenotyping)At diagnosis and at severe asthma assessmentCompleted todayEosinophils 0.42 two weeks ago; total IgE 210; house dust mite specific IgE positive; cat, dog, cockroach and mold negative
ImagingEchocardiogram, with BNP and chest X-ray from the first visitTo exclude heart failure when breathlessness is unexplained; for stage 2 hypertension or LVHCompleted todayEjection fraction 62 percent; mild concentric LVH; grade 1 diastolic dysfunction; BNP 48 two weeks ago
SurveyAsthma Control Test, symptoms, night waking and reliever useEvery visitCompleted todayAsthma Control Test 14; night waking two or three times a week; albuterol most days
ExaminationInhaler technique with her own inhaler, and adherenceEvery visit; before any step-upCompleted todayTaught today with her new inhaler; demonstrated correctly
Self-managementWritten asthma action planEvery visit and after every exacerbationCompleted todayWritten plan with peak flow zones given
Self-managementExacerbation history (oral corticosteroid courses, emergency visits, admissions)Every visitCompleted todayNo oral corticosteroid course, emergency visit or admission in the past year
Self-managementStep-up or step-down assessment (GINA track 1)Every visitCompleted todayStarting at step 3: low-dose budesonide-formoterol maintenance and reliever
Self-managementTriggers, exposures and smoking or vapingEvery visitCompleted todayNever smoker; dust, colds, perfume and humid air; dust mite covers advised because she is sensitized
ExaminationComorbidities: rhinosinusitis, reflux, obesity, sleep apnea screen, moodAt diagnosis and yearlyCompleted todayNasal symptoms (ear, nose and throat referral), reflux (omeprazole), BMI 33.0; STOP-BANG 2 (low risk); PHQ-2 1 at the first visit
Self-managementVaccinationsYearlyCompleted todayPCV20 today; influenza and COVID-19 vaccines due in the autumn; RSV due
ReferralBiologic assessmentWhen asthma is severe or uncontrolled despite optimized step 4 to 5 treatmentNot indicatedNot yet: treatment has only now started
ExaminationBlood pressure in clinic and at homeEvery visit; home readings at diagnosis and after changesCompleted todayClinic 146/86; home average 144/84 over seven days
ExaminationFundoscopic examinationYearly in hypertensionCompleted todayMild arteriolar narrowing
LaboratoryBaseline hypertension tests: kidney function, potassium, glucose or A1c, lipids, urine albumin, TSH; ECGAt diagnosis, then yearlyUp to dateAll drawn at the first visit: creatinine 0.92, potassium 4.1, A1c 5.9 percent, LDL 144, urine albumin-to-creatinine ratio 18, TSH 2.2; ECG with LVH by voltage
Self-managementEquity: race-neutral lung function interpretation and plain explanationEvery testCompleted todayRead with GLI Global equations; results explained to her in plain words

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Am Coll Cardiol 2022;79(17):1757-1780 (PMID 35379504) (2022); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023)

Follow-up: Six-week review. Ear, nose and throat in four weeks. Follow the action plan: two extra inhalations and a call to the clinic if in the yellow zone for more than a day; emergency care in the red zone. Next scheduled visit 2026-05-04: six-week asthma review: control, inhaler technique and adherence, the ear, nose and throat result, blood pressure and reflux. [S]